Alloy Therapeutics
Alloy Therapeutics offers a range of biologics discovery services, including therapeutic antibody discovery, TCR discovery, and genetic medicines, and operates research sites across the US and Europe.
Services
Alloy Therapeutics offers a diverse range of biologics discovery services. These include therapeutic antibody discovery, TCR discovery, and genetic medicines. The company aims to provide comprehensive support in the early stages of drug development, helping partners to advance their research and bring new therapies to market.
ATX-Gx™ Transgenic Mice Platform
Alloy Therapeutics provides the ATX-Gx™ transgenic mice platform, which is designed for antibody discovery. The platform is offered under a royalty-free licensing model, enabling researchers to access and utilize this resource without financial burdens tied to royalty fees. This approach encourages broader use and collaboration within the scientific community.
AntiClastic™ ASO Format
The AntiClastic™ ASO format is one of Alloy Therapeutics' proprietary developments. This format enhances the potency and delivery of antisense oligonucleotides (ASOs), potentially improving the effectiveness of these genetic medicines. By focusing on these advancements, Alloy Therapeutics aims to contribute significantly to the field of genetic medicine.
Global Research Sites
Alloy Therapeutics operates five research sites across multiple locations, including Boston, MA; Cambridge, UK; Basel, CH; Athens, GA; and a headquarters in Waltham, MA. These sites enable the company to conduct cutting-edge research and collaborate with a global network of partners.
82VS Venture Studio Model
Alloy Therapeutics employs a venture studio model called 82VS, which supports the creation and development of new drug companies. This model facilitates the incubation of early-stage ventures, providing them with the necessary resources and expertise to advance their drug discovery efforts.